Ocular hypertension management in long-term treatments with intravitreal dexamethasone implants: a 3-year experience
V. 171 N. 1 (2020), Case report
V. 171 N. 1 (2020)

Ocular hypertension management in long-term treatments with intravitreal dexamethasone implants: a 3-year experience: doi: 10.7417/CT.2020.2182

Case report
Pubblicato 2020-01-10
R. Monsellato
Department of Organs of Sense, Sapienza University of Rome
E. Trovato
Department of Organs of Sense, Sapienza University of Rome
P. Turchetti
National Institute for Health, Migration and Poverty (INMP/NIHMP), Rome
M. Forestiere
Department of Organs of Sense, Sapienza University of Rome
A. Pistone
Department of Organs of Sense, Sapienza University of Rome
S. De Sio
Department SAIMLAL “Anatomical Histological Medical and Legal Sciences of the Locomotor Apparatus” Sapienza University of Rome, Italy
L. Accetta
Department of Organs of Sense, Sapienza University of Rome
F. Pacella
Department of Organs of Sense, Sapienza University of Rome
PDF

Parole chiave

Ozurdex®
Dexamethasone
Glaucoma
Intraocular pressure
Ocular hypertension

Abstract

Purpose
A commonly recognized complication of intravitreal steroids is ocular hypertension (OHT).The aim of this study was to investigate the effectiveness of pharmacotherapy in controlling this side effect, even in patients receiving sequential injections.

Methods
A total of 146 injections were performed on 78 patients over 3 years. 78 eyes were treated with 1 injection, 44 eyes were treated with 2 injections; 24 eyes were treated with 3 injections. The intravitreal corticosteroid used in this observational study is 0.7mg dexamethasone, commercially known as 0.7mg Ozurdex®.

Results
Following the first injection, mean intraocular pressure (IOP) increased by 1,90 mmHg. Following the second injection, mean IOP increased by 0.23 mmHg. Following the third injection, there was no statistically significant change. Patients with IOP >= 21mmHg (7% of all participants) were started on topical pressure-lowering medications.

Conclusion
Intravitreal dexamethasone implants increased IOP of variable degrees in different patients. However, secondary OHT was effectively controlled with pharmacotherapy alone. This allowed for continuation of dexamethasone therapy

PDF